Nowadays, treatment of HNSCC is surgical resection and postoperative radiotherapy according to the tumor stage and origin site.17, 18There is no evidence in clinical trials of SNC-targeted therapy, but there were some effective in vitro experiments of exon 20 mutation SNC by epidermal growth factor receptor gene (EGFR) exon 20 inhibitor targeted therapy, neratinib, which sparked a debate about the viability of SNC treatment.19, 20On the other hand, the treatments in OC, OPC, and LC have gained potential to use targeted therapy and immunotherapy, such as nivolumab and cetuximab. The gene discussed is EGFR; the disease is laryngotracheoesophageal cleft.